Stratec Biomedical (ETR:SBS) has been given a €59.00 ($70.24) target price by analysts at Berenberg Bank in a report issued on Thursday. The brokerage currently has a “neutral” rating on the stock. Berenberg Bank’s price objective would indicate a potential downside of 13.74% from the company’s previous close.

SBS has been the subject of several other reports. Oddo Bhf set a €58.00 ($69.05) price objective on Stratec Biomedical and gave the company a “neutral” rating in a report on Monday, October 23rd. Deutsche Bank set a €56.00 ($66.67) price objective on Stratec Biomedical and gave the company a “neutral” rating in a report on Tuesday, October 24th. Warburg Research set a €62.00 ($73.81) price objective on Stratec Biomedical and gave the company a “buy” rating in a report on Thursday, October 26th. Finally, Kepler Capital Markets set a €70.00 ($83.33) target price on Stratec Biomedical and gave the company a “buy” rating in a report on Friday, October 27th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of €60.50 ($72.02).

Shares of Stratec Biomedical (SBS) opened at €68.40 ($81.43) on Thursday. Stratec Biomedical has a 52-week low of €41.30 ($49.17) and a 52-week high of €69.85 ($83.15).

COPYRIGHT VIOLATION WARNING: “Berenberg Bank Reiterates “€59.00” Price Target for Stratec Biomedical (SBS)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/berenberg-bank-reiterates-59-00-price-target-for-stratec-biomedical-sbs.html.

About Stratec Biomedical

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.